Daxor Announces Two Significant New Customer Transactions With The Co's BVA-100 In January; No Financial Terms Disclosed

Author: Benzinga Newsdesk | February 12, 2024 09:15am

Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor's BVA-100™ (Blood Volume Analyzer) in January, marking a strong start to 2024.

 

New wins include:

• Four-year lease agreement for the BVA analyzer at an award-winning network of 24 affiliated hospitals in Mississippi, West Tennessee, and East Arkansas with a reach into Kentucky, Missouri, and central Alabama
• BVA analyzer purchase at a 200-bed independent hospital in Mississippi

Interventional cardiologist Dr. Aaron Earles, a clinical user at a new account had this to say, "We started using BVA in our hospital and the results have been astounding. We are shortening our length of stay as well. We are also finding that people we thought were in chronic heart failure were intravascularly volume depleted and anemic. It is a game-changer. It helps us preserve renal function as well."

"Our sales and marketing teams have kicked off the new calendar year with great momentum," said Michael Feldschuh, Daxor's CEO and President. "We remain focused on commercialization - broadening our reach with new analyzer purchases, and driving utilization within our current customer base, supported by our ezBVA Lab service."

Posted In: DXR